Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  BioMarin Pharmaceutical Inc.    BMRN   US09061G1013

 SummaryQuotesChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
04/16/2014 04/17/2014 04/21/2014 04/22/2014 04/23/2014 Date
61.37(c) 60.89(c) 61.34(c) 61.99(c) 59.19(c) Last
2 129 789 1 838 811 1 284 722 2 592 343 1 993 424 Volume
+5.43% -0.78% +0.74% +1.06% -4.52% Change
More quotes
Company
BioMarin Pharmaceutical, Inc. develops and commercializes innovative pharmaceuticals for serious diseases and medical conditions. The company's product portfolio is comprised of four approved products and multiple investigational product candidates which include Naglazyme, Kuvan, Aldurazyme and... 
Sector
Pharmaceuticals - Diversified
Calendar
05/01 | 05:00pmEarnings Call
Surperformance© rating of BioMarin Pharmaceutical In
Trading Rating : Investor Rating :
More about the company
Chart BIOMARIN PHARMACEUTICAL IN
Duration : Period :
BioMarin Pharmaceutical In Technical Analysis Chart | BMRN | US09061G1013 | 4-Traders
Full-screen chart
Financials ($)
Sales 2014 674 M
EBIT 2014 -234 M
Net income 2014 -263 M
Debt 2014 194 M
Yield 2014 -
Sales 2015 842 M
EBIT 2015 -139 M
Net income 2015 -151 M
Debt 2015 255 M
Yield 2015 -
PER 2014 -
PER 2015
EV / Sales 2014 13,4x
EV / Sales 2015 10,8x
Capitalization 8 810 M
More Financials
Latest news on BIOMARIN PHARMACEUTICAL IN
04/16 BIOMARIN PHARMACEUTICAL : to Host First Quarter 2014 Financial Results Conferenc..
04/14 BIOMARIN PHARMACEUTICAL : FDA Extends Market Exclusivity Six Months for BioMarin..
04/11 BIOMARIN PHARMACEUTICAL : Clinical Trial Results and Initiation, Endowment, Prod..
03/25 BIOMARIN PHARMACEUTICAL : Change in Directors or Principal Officers, Financial S..
03/21 BIOMARIN PHARMACEUTICAL : Appoints Pioneer in Personalized Medicine, Dennis J. S..
03/19 BIOMARIN PHARMACEUTICAL : Findings on Colon Cancer Reported by Investigators at ..
03/19 BIOMARIN PHARMACEUTICAL : Details Findings in Clinical Trials and Studies
03/13 BIOMARIN PHARMACEUTICAL : Termination of a Material Definitive Agreement, Comple..
03/13 BIOMARIN PHARMACEUTICAL : Food and Drug Administration Issues Priority Review Vo..
03/12 BIOMARIN PHARMACEUTICAL : Issuance of Priority Review Voucher; Rare Pediatric Di..
03/11 Audentes Therapeutics Strengthens Its Leadership Team
03/06 BIOMARIN PHARMACEUTICAL INC. : BIOMARIN PHARMACEUTICAL INC FILES (8-K) Disclosin..
More news
Comments 
Advertisement
Technical analysis trends
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Technical analysis
Income Statement Evolution
BioMarin Pharmaceutical In : Income Statement Evolution
More Financials
EPS Revisions
BioMarin Pharmaceutical In : EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF